Gene Mutations in the Succinate Dehydrogenase Subunit SDHB Cause Susceptibility to Familial Pheochromocytoma and to Familial Paraganglioma
Open accessThe DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.
Abstract
The pheochromocytomas are an important cause of secondary hypertension. Although pheochromocytoma susceptibility may be associated with germline mutations in the tumor-suppressor genes VHL and NF1 and in the proto-oncogene RET, the genetic basis for most cases of nonsyndromic familial pheochromocytoma is unknown. Recently, pheochromocytoma susceptibility has been associated with germline SDHD mutations. Germline SDHD mutations were originally described in hereditary paraganglioma, a dominantly inherited disorder characterized by vascular tumors in the head and the neck, most frequently at the carotid bifurcation. The gene products of two components of succinate dehydrogenase, SDHC and SDHD, anchor the gene products of two other components, SDHA and SDHB, which form the catalytic core, to the inner-mitochondrial membrane. Although mutations in SDHC and in SDHD may cause hereditary paraganglioma, germline SDHA mutations are associated with juvenile encephalopathy, and the phenotypic consequences of SDHB mutations have not been defined. To investigate the genetic causes of pheochromocytoma, we analyzed SDHB and SDHC, in familial and in sporadic cases. Inactivating SDHB mutations were detected in two of the five kindreds with familial pheochromocytoma, two of the three kindreds with pheochromocytoma and paraganglioma susceptibility, and 1 of the 24 cases of sporadic pheochromocytoma. These findings extend the link between mitochondrial dysfunction and tumorigenesis and suggest that germline SDHB mutations are an important cause of pheochromocytoma susceptibility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“germline mutations in the B, C and D subunits of SDH predispose individuals to hereditary paragangliomatosis with phaeochromocytomas (HPGL) (2 -6)”
From Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations (2005) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, a biallelic loss of succinate dehydrogenase (SDH), an alteration found in familial paragangliomas and pheochromocytomas, as well as in a subset of sporadic gastrointestinal stromal tumors, creates a build-up of succinate (Astuti et al., 2001; Janeway et al., 2011).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Astuti et al., 2001
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The results of a clinical study further confirmed this observation by showing that patients with nonmetastatic lung cancer harbored loss-of-function mutations in SDH5128.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [128]
Experimental — accuracy not yet measuredIn the citing paper
“In cancer cells, mutations in succinate dehydrogenase subunit B (SDHB) cause susceptibility to familial pheochromocytoma99 and familial paraganglioma100 as well as gastrointestinal stromal tumors101.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [99]
In the citing paper
“In addition to the tumorigenic effects of succinate accumulation, SDH5 mutation is the key driver supporting the acquisition of epithelial–mesenchymal transition (EMT) characteristics.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [128]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Green, D. R., & Reed, J. C. (1998) · Science · doi:10.1126/science.281.5381.1309 · Cited by 8,965
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180 · cited 2×
“…cancers and in mouse models, results in up-regulation of angiogenic growth factors, such as vascular endothelial growth factor, secondary to a defect in ubiquitylation of the a-subunits of the HIF-1 and the HIF-2 transcription factors (Maxwell et al. 1999; Cockman et al. 2000; Ohh et al. 2000).”
BackgroundSelf-citationMutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638 · cited 3×
“…the iron-sulfur–protein subunit) and in both SDHC and SDHD (i.e., the genes for the integral membrane–protein subunits) are associated with neoplasia (Baysal et al. 2000; Niemann and Muller 2000; present study), autosomal recessive homozygous SDHA (i.e., the gene for the flavoprotein subunit)…”
BackgroundOhh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577 · cited 2×
“…cancers and in mouse models, results in up-regulation of angiogenic growth factors, such as vascular endothelial growth factor, secondary to a defect in ubiquitylation of the a-subunits of the HIF-1 and the HIF-2 transcription factors (Maxwell et al. 1999; Cockman et al. 2000; Ohh et al. 2000).”
BackgroundCockman, M. E., Masson, N., Mole, D. R., Jaakkola, P., Chang, G.-W., Clifford, S. C., Maher, E. R., Pugh, C. W., Ratcliffe, P. J., & Maxwell, P. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002740200 · Cited by 1,050 · cited 1×
“…cancers and in mouse models, results in up-regulation of angiogenic growth factors, such as vascular endothelial growth factor, secondary to a defect in ubiquitylation of the a-subunits of the HIF-1 and the HIF-2 transcription factors (Maxwell et al. 1999; Cockman et al. 2000; Ohh et al. 2000).”
BackgroundSelf-citationMutations in SDHC cause autosomal dominant paraganglioma, type 3
Niemann, S., & Müller, U. (2000) · Nature Genetics · doi:10.1038/81551 · Cited by 875 · cited 4×
“…herein: PGL1 (MIM 168000), which results from SDHD mutations at 11q23; PGL2 (MIM 601650), which maps to 11q13, although the causative gene has not been identified (Mariman et al. 1995); and PGL3 (MIM 605373), which results from SDHC mutations at 1q21 (Baysal et al. 2000; Niemann and Muller 2000).”
BackgroundInfluentialBourgeron, T., Rustin, P., Chretien, D., Birch-Machin, M., Bourgeois, M., Viegas-Péquignot, E., Munnich, A., & Rötig, A. (1995) · Nature Genetics · doi:10.1038/ng1095-144 · Cited by 730 · cited 2×
“SDHA mutations are associated with juvenile encephalopathy (Bourgeron et al. 1995), and the phenotypic consequences of SDHB mutations have not been defined.”
BackgroundHoffman, M. A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1019 · Cited by 382 · cited 1×
“Interestingly, germline VHL mutations that predispose patients to pheochromocytoma do not impair HIF-1a ubiquitylation (Clifford et al. 2001; Hoffman et al. 2001).”
BackgroundClifford, S. C. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1029 · Cited by 373
Gimm, O., Armanios, M. Y., Dziema, H., Neumann, H. P. H., & Eng, C. (2000) · PubMed · Cited by 274
Self-citation
Cited by
Items 301–400 of 999
Metabolic implications of hypoxia and pseudohypoxia in pheochromocytoma and paraganglioma
Kľučková, K., & Tennant, D. A. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2801-6 · Cited by 70
“…years, mutations in the other three SDH genes (A, B and C) and its assembly factor (SDHAF2) were also observed, adding considerable evidential weight to SDHx genes being critical tumour suppressors linked to PPGL (Astuti et al. 2001; Burnichon et al. 2010; Hao et al. 2009; Niemann and Muller 2000).”
BackgroundHereditary phaeochromocytomas and paragangliomas: a study of five susceptibility genes
Bauters, C., Vantyghem, M., Leteurtre, E., Odou, M., Mouton, C., Porchet, N., Wemeau, J.-L., Proye, C., & Pigny, P. (2003) · Journal of Medical Genetics · doi:10.1136/jmg.40.6.e75 · Cited by 69
Challenges in Paragangliomas and Pheochromocytomas: from Histology to Molecular Immunohistochemistry
Juhlin, C. C. (2021) · Endocrine Pathology · doi:10.1007/s12022-021-09675-0 · Cited by 72
The Genetic Basis of Pheochromocytoma
Gimm, O., Koch, C. A., Januszewicz, A., Opocher, G., & INeumann, H. P. H. (2003) · KARGER eBooks · doi:10.1159/000074657 · Cited by 70
GEP- NETS UPDATE: Genetics of neuroendocrine tumors
Crona, J., & Skogseid, B. M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-0972 · Cited by 85
Hypoxia and Hypoxia Inducible Factors (HIF) as Important Regulators of Tumor Physiology
Acker, T., & Plate, K. H. (2004) · Cancer treatment and research · doi:10.1007/978-1-4419-8871-3_14 · Cited by 75
Solid tumors associated with multiple endocrine neoplasias
Almeida, M. Q., & Stratakis, C. A. (2010) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2010.09.006 · Cited by 66
“CarneyeStratakis syndrome Recently, germ line SDHB, SDHC, and SDHD mutations were identified in patients with both gastrointestinal stromal tumors and paragangliomas.”
InfluentialThe role of mitochondrial electron transport in tumorigenesis and metastasis
Tan, A. S., Baty, J. W., & Berridge, M. V. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.10.016 · Cited by 76
Metabolic synthetic lethality in cancer therapy
Zecchini, V. R., & Frezza, C. (2016) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2016.12.003 · Cited by 66
Succinate dehydrogenase (SDH) deficiency, Carney triad and the epigenome
Settas, N., Faucz, F. R., & Stratakis, C. A. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.07.018 · Cited by 71
Sudarshan, S., Pinto, P. A., Neckers, L., & Linehan, W. M. (2007) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0711 · Cited by 65
“Mutations in subunits B, C, and D of the succinate dehydrogenase complex have all been linked to hereditary paraganglioma”
BackgroundGenetic Testing for Pheochromocytoma
Karásek, D., Fryšák, Z., & Pacák, K. (2010) · Current Hypertension Reports · doi:10.1007/s11906-010-0151-1 · Cited by 67
“The syndrome is caused by inactivating mutations of the tumor suppressor SDHB gene located on chromosome 1p35–p36 [2, 3, 30 ].”
BackgroundSDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors
Italiano, A., Chen, C.-L., Sung, Y., Singer, S., DeMatteo, R. P., LaQuaglia, M. P., Besmer, P., Socci, N. D., & Antonescu, C. R. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-408 · Cited by 66
“However, this vision has been recently challenged by the finding that a significant proportion of familial and apparently sporadic paraganglioma and pheochromocytoma are related to germline somatic mutation of genes encoding proteins of SDH complex II [21-25].”
BackgroundYeap, P. M., Tobias, E. S., Mavraki, E., Fletcher, A. J., Bradshaw, N., Freel, E. M., Cooke, A., Murday, V. A., Davidson, H. R., Perry, C. G., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1244 · Cited by 69
Rinaldi, G., Rossi, M., & Fendt, S. (2018) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1397 · Cited by 63
“Most dramatic variations of these metabolites, resulting in DNA and histone hypermethylation, are observed in cancers with mutations in TCA cycle enzymes: mutations in SDH leading to the loss of enzyme expression, and consequently to succinate accumulation, are frequently found in paraganglioma, pheochromocytoma, gast…”
BackgroundTumours of familial origin in the head and neck
Suarez, C. M., Rodrigo, J. P., Ferlito, A., Cabanillas, R., Shaha, A. R., & Rinaldo, A. (2006) · Oral Oncology · doi:10.1016/j.oraloncology.2006.03.002 · Cited by 79
Cancer metabolism and intervention therapy
Zhao, H., & Li, Y. (2021) · Molecular Biomedicine · doi:10.1186/s43556-020-00012-1 · Cited by 74
RECENT ADVANCES IN THE GENETICS OF PHAEOCHROMOCYTOMA AND FUNCTIONAL PARAGANGLIOMA
Gimenez‐Roqueplo, A., Burnichon, N., Amar, L., Favier, J., Jeunemaître, X., & Plouin, P. (2008) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2008.04881.x · Cited by 66
MANAGEMENT OF ENDOCRINE DISEASE: Clinical management of paragangliomas
Corssmit, E. P. M., & Romijn, J. A. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0396 · Cited by 67
New Insights into the Genetics of Familial Chromaffin Cell Tumors
Koch, C. A., Vortmeyer, A. O., Zhuang, Z., Brouwers, F. M., & Pacák, K. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04409.x · Cited by 64
Baysal, B. E., & Maher, E. R. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0226 · Cited by 64
“…were reported to cause familial HNPGL (inherited as an autosomal dominant trait without parentof-origin effects) (Niemann & Muller 2000) and germline SDHB (PGL4) mutations were found to cause inherited susceptibility to HNPGL and pheochromocytomas and paragangliomas (PPGL) (Astuti et al. 2001b).”
BackgroundSelf-citationCurrent management of succinate dehydrogenase–deficient gastrointestinal stromal tumors
Neppala, P., Banerjee, S., Fanta, P. T., Yerba, M., Porras, K., Burgoyne, A. M., & Sicklick, J. K. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09818-0 · Cited by 62
Glioblastoma Metabolism: Insights and Therapeutic Strategies
Bernhard, C., Reita, D., Martin, S., Entz‐Werlé, N., & Dontenwill, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119137 · Cited by 68
“Examples of such mutations include the succinate dehydrogenase mutation, linked to the development of paragangliomas [196], and the IDH mutations, commonly found in gliomas and serving as important diagnostic, prognostic, and predictive biomarkers for a favorable response to TMZ in glioma patients [10].”
BackgroundClinical Features of Paraganglioma Syndromes
Boedeker, C. C., Neumann, H., Offergeld, C., Maier, W., Falcioni, M., Berlis, A., & Schipper, J. (2009) · Skull base · doi:10.1055/s-0028-1103123 · Cited by 66
“It soon became clear that patients with PGL 1 and PGL 4 also harbor a risk for the development of pheochromocytomas.(8,15,17) A considerable number of HNP and pheochromocytoma patients with mutations of the SDHB or SDHD gene have been recorded in the last 8 years.”
BackgroundMargetts, C. D. E., Astuti, D., Gentle, D., Cooper, W. N., Cascón, A., Catchpoole, D. R., Robledo, M., Neumann, H. P. H., Latif, F., & Maher, E. R. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00865 · Cited by 65
“Previously we and others demonstrated frequent CASP8 methylation in neuroblastoma (Teitz et al. 2000, Astuti et al. 2001c), and we have now also demonstrated that CASP8 methylation occurs often in phaeochromocytoma.”
BackgroundInfluentialSelf-citationSuccinate dehydrogenase deficiency in pediatric and adult gastrointestinal stromal tumors
Belinsky, M. G., Rink, L., & von Mehren, M. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00117 · Cited by 66
“Germline mutations in SDHD (Baysal et al., 2000), SDHC (Niemann and Muller, 2000), and SDHB (Astuti et al., 2001) are associated with the familial PGL/PHEO syndromes PGL1 (OMIM 16800), PGL2 (OMIM 601650), and PGL4 (OMIM 115310), respectively.”
BackgroundInfluentialMacFarlane, J., Seong, K. C., Bisambar, C., Madhu, B., Allinson, K. S. J., Marker, A. J., Warren, A. Y., Park, S., Giger, O., Challis, B., et al. (2020) · Clinical Endocrinology · doi:10.1111/cen.14289 · Cited by 70
Self-citationMutations of the SDHB and SDHD genes
Pawlu, C., Bausch, B., & Neumann, H. P. H. (2005) · Familial Cancer · doi:10.1007/s10689-004-4227-4 · Cited by 65
“[18] 6 725 del C + Gimenez-Roqueplo et al.”
BackgroundSelak, M. A., Durán, R. V., & Gottlieb, E. (2006) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2006.05.015 · Cited by 59
Máximo, V., Lima, J. P., Soares, P., & Sobrinho-Simões, M. A. (2009) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-009-0766-2 · Cited by 73
“[4], other studies showed that also SDHB and SDHC, which encode two other subunits of SDH, are mutated in familial PGL and phaeochromocytomas [5, 6].”
ResultAssembly of mitochondrial succinate dehydrogenase in human health and disease
Cao, K. J., Xu, J., Cao, W., Wang, X., Lv, W., Zeng, M., Zou, X., Liu, J., & Feng, Z. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.07.023 · Cited by 68
Nervous system involvement in von Hippel–Lindau disease: pathology and mechanisms
Vortmeyer, A. O., Falke, E., Gläsker, S., Li, J., & Oldfield, E. H. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1091-z · Cited by 62
“matosis 1 [129], and the paraganglioma/pheochromocytoma syndromes that are caused by germline mutations of SDHB [7], SDHC [6], SDHD [11, 129].”
BackgroundGermline and mosaic mutations causing pituitary tumours: genetic and molecular aspects
Pepe, S., Korbonits, M., & Iacovazzo, D. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0446 · Cited by 65
Genetic basis of phaeochromocytoma and paraganglioma
Benn, D. E., & Robinson, B. G. (2006) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2006.07.005 · Cited by 59
Identification of novel SDHD mutations in patients with phaeochromocytoma and/or paraganglioma
Cascón, A., Ruiz‐Llorente, S., Cebrián, A., Tellería, D., Rivero, J. C., Díez, J. J., Lopez-Ibarra, P. J., Jaunsolo, M. A., Benitez, J. J., & Robledo, M. (2002) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5200829 · Cited by 62
Taïeb, D., Yang, C., Delenne, B., Zhuang, Z., Barlier, A., Sebag, F., & Pacak, K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1217 · Cited by 55
“The reported extension of the syndrome to PHEO is similar to pioneering studies that showed that germline VHL mutations can be associated with head and neck PGL (HNPGL) (20), SDHB mutations (succinate dehydrogenase complex II, subunit B) also with HNPGL (21) or with PHEO (22), RET mutations with rarely found PGL (20),…”
ResultBuza, N., Xu, F., Wu, W., Carr, R. J., Li, P., & Hui, P. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.05.010 · Cited by 56
Model animals for the study of oxidative stress from complex II
Ishii, T., Miyazawa, M., Onouchi, H., Yasuda, K., Hartman, P. S., & Ishii, N. (2012) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2012.10.016 · Cited by 65
“Following the discovery of SDHD (OMIM ID: 602690) as the gene responsible for PGL1 in familial HNPGLs [53], it was subsequently recognized that two other subunits of this mitochondrial enzyme, SDHC (PGL3, OMIM ID: 602413) and SDHB (PGL4, OMIM ID: 185470) were associated with heritable PHEO and⁄or PGL [54,55].”
BackgroundInfluentialGamma Knife radiosurgery for glomus jugulare tumors: a single-center series of 75 cases
Ibrahim, R., Ammori, M. B., Yianni, J., Grainger, A., Rowe, J. G., & Radatz, M. W. R. (2016) · Journal of neurosurgery · doi:10.3171/2016.4.jns152667 · Cited by 61
Diagnosis and management of pheochromocytoma
Hodin, R. A., Lubitz, C. C., Phitayakorn, R., & Stephen, A. E. (2014) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2013.12.001 · Cited by 59
“due to a mutation in one of the succinate dehydrogenase (SDH) subunit genes (succinate dehydrogenase-B [SDHB]).(24) Studies have investigated the variation in clinical presentation in patients with PCC and one of the predisposing genetic syndromes.”
BackgroundParasympathetic Paragangliomas Are Part of the Von Hippel-Lindau Syndrome
Gaal, J., van Nederveen, F. H., Erlic, Z., Korpershoek, E., Oldenburg, R. A., Boedeker, C. C., Kontny, U., Neumann, H. P. H., Dinjens, W. N. M., & de Krijger, R. R. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1479 · Cited by 60
Penetrance and clinical consequences of a gross SDHB deletion in a large family
Solis, D. C., Burnichon, N., Timmers, H., Raygada, M. J., Kozupa, A., Merino, M. J., Makey, D., Adams, K. T., Vénisse, A., Gimenez‐Roqueplo, A., et al. (2009) · Clinical Genetics · doi:10.1111/j.1399-0004.2009.01157.x · Cited by 57
“However, the phenotype associated with large SDHB deletions is not well known as these mutations are rare and missed by standard direct sequencing methods (3, 6, 10).”
BackgroundHigh prevalence of founder mutations of the succinate dehydrogenase genes in the Netherlands
Hensen, E. F., van Duinen, N., Jansen, J. C., Corssmit, E. P. M., Tops, C., Romijn, J. A., Vriends, A. H. J. T., van der Mey, A., Cornelisse, C., Devilee, P., et al. (2011) · Clinical Genetics · doi:10.1111/j.1399-0004.2011.01653.x · Cited by 63
Astuti, D., Ricketts, C. J., Chowdhury, R., McDonough, M. A., Gentle, D., Kirby, G., Schlisio, S., Kenchappa, R. S., Carter, B. D., Kaelin, W. G., et al. (2010) · Endocrine Related Cancer · doi:10.1677/erc-10-0113 · Cited by 55
Self-citationPrecision medicine in pheochromocytoma and paraganglioma: current and future concepts
Björklund, P., Pacák, K., & Crona, J. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12507 · Cited by 68
Carney Triad, Carney-Stratakis Syndrome, 3PAS and Other Tumors Due to SDH Deficiency
Pitsava, G., Settas, N., Faucz, F. R., & Stratakis, C. A. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.680609 · Cited by 61
“Germline mutations of SDHB, SDHC, and SDHD genes are responsible for approximately 50% of hereditary paragangliomas (4, 24, 25, 35–38) and pheochromocytomas (24, 36, 39).”
BackgroundHensen, E. F., Siemers, M., Jansen, J. C., Corssmit, E. P. M., Romijn, J. A., Tops, C. M. J., van der Mey, A. G. L., Devilee, P., Cornelisse, C. J., Bayley, J., et al. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04097.x · Cited by 58
Phenotypic variability of mitochondrial disease caused by a nuclear mutation in complex II
Pagnamenta, A. T., Hargreaves, I. P., Duncan, A. J., Taanman, J., Heales, S., Land, J. M., Bitner-Glindzicz, M. A. K., Leonard, J. V., & Rahman, S. (2006) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2006.05.003 · Cited by 62
An update on the genetics of pheochromocytoma
Karásek, D., Shah, U., Fryšák, Z., Stratakis, C. A., & Pacák, K. (2012) · Journal of Human Hypertension · doi:10.1038/jhh.2012.20 · Cited by 58
Lima, J., Feijão, T., Ferreira da Silva, A., Pereira-Castro, I., Fernandez-Ballester, G., Máximo, V., Herrero, A., Serrano, L., Sobrinho-Simões, M., & Garcia-Rostan, G. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0640 · Cited by 54
Paraganglioma and pheochromocytoma upon maternal transmission of SDHDmutations
Bayley, J., Oldenburg, R. A., Nuk, J., Hoekstra, A. S., van der Meer, C. A., Korpershoek, E., McGillivray, B., Corssmit, E. P. M., Dinjens, W. N. M., de Krijger, R. R., et al. (2014) · BMC Medical Genetics · doi:10.1186/s12881-014-0111-8 · Cited by 63
“1p36) [5], SDHC (chromosome 1q23) [6], SDHAF2 (chromosome 11q12.”
Succinate Dehydrogenase and Ribonucleic Acid Networks in Cancer and Other Diseases
Moreno, C., Santos, R. M., Burns, R., & Zhang, W. C. (2020) · Cancers · doi:10.3390/cancers12113237 · Cited by 62
“Mutations in SDHB [29], SDHC [30], and SDHD [31] have been implicated in causing two rare tumors in the autonomic nervous system known as paraganglioma (PGL) and pheochromocytoma (PCC) [32].”
BackgroundGaster, M., Nehlin, J. O., & Minet, A. D. (2012) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2012.656653 · Cited by 63
Sdhd and Sdhd/H19 Knockout Mice Do Not Develop Paraganglioma or Pheochromocytoma
Bayley, J.-P., van Minderhout, I., Hogendoorn, P. C. W., Cornelisse, C. J., van der Wal, A., Prins, F. A., Teppema, L., Dahan, A., Devilee, P., & Taschner, P. E. M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007987 · Cited by 53
“1p36) [3] were implicated in paragangliomas.”
Succinate Dehydrogenase Loss in Familial Paraganglioma: Biochemistry, Genetics, and Epigenetics
Her, Y. F., & Maher, L. J. (2015) · International Journal of Endocrinology · doi:10.1155/2015/296167 · Cited by 58
“The PGL syndrome associated with SDHB gene mutations was identified by Astuti and colleagues [74]; see [75, 76].”
BackgroundSudarshan, S., Shanmugasundaram, K., Naylor, S. L., Lin, S., Livi, C. B., O'Neill, C. F., Parekh, D. J., Yeh, I.-T., Sun, L.-Z., & Block, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021037 · Cited by 52
“Multiple other genes encoding enzymes of the tricarboxylic (TCA) cycle are considered tumor suppressor genes including SDHB, SDHC, and SDHD (Succinate Dehydrogenase subunits B,C,D) [32,33,34].”
BackgroundProtein lysine acetylation guards metabolic homeostasis to fight against cancer
Xu, W., Li, Y., LIU, C., & Zhao, S. (2013) · Oncogene · doi:10.1038/onc.2013.163 · Cited by 58
Dahia, P. L. M., Clifton-Bligh, R. J., Gimenez‐Roqueplo, A., Robledo, M., & Jiménez, C. (2020) · Endocrine Related Cancer · doi:10.1530/erc-19-0435 · Cited by 58
Self-citationMitochondrial Genetic and Epigenetic Regulations in Cancer: Therapeutic Potential
Wagner, A., Kosnacova, H., Chovanec, M., & Jurkovičová, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147897 · Cited by 57
Mitochondrial redox adaptations enable alternative aspartate synthesis in SDH-deficient cells
Hart, M. L., Quon, E., Vigil, A.-L. B. G., Engström, I., Newsom, O. J., Davidsen, K., Hoellerbauer, P., Carlisle, S. M., & Sullivan, L. B. (2023) · eLife · doi:10.7554/elife.78654 · Cited by 54
“Biallelic lossoffunction mutations to the subunits of SDH (A- D) or SDH assembly factors (SDHAF12), can lead to neoplasms in neuroendocrine tissues and the kidney (Astuti et al., 2001; Bardella et al., 2011; Baysal et al., 2000; Burnichon et al., 2010; Hao et al., 2009; Niemann and Müller, 2000).”
Genetic Basis of Cancer of the Kidney
Sudarshan, S., & Linehan, W. M. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.06.008 · Cited by 57
Molatore, S., Liyanarachchi, S., Irmler, M., Perren, A. A., Mannelli, M., Ercolino, T., Beuschlein, F., Jarząb, B., Włoch, J., Ziaja, J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003956107 · Cited by 51
Succinate dehydrogenase expression in breast cancer
Kim, S., Kim, D. H., Jung, W.-H., & Koo, J. S. (2013) · SpringerPlus · doi:10.1186/2193-1801-2-299 · Cited by 60
“…in several tumor types, including pheochromocytomas (Van Nederveen et al. 2009; Astuti et al. 2001), paragangliomas (Van Nederveen et al. 2009; Astuti et al. 2001; Baysal 2003; Burnichon et al. 2010), GISTs (Gaal et al. 2011; Gill et al. 2010b; Gill et al. 2011a), and renal cell Figure 2…”
InfluentialCasey, R. T., Ascher, D. B., Rattenberry, E., Izatt, L., Andrews, K. A., Simpson, H. L., Challis, B., Park, S., Bulusu, V. R., Lalloo, F., et al. (2017) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.279 · Cited by 51
“…PCC/PGL, germline mutations are most frequently identified in SDHB and SDHD (Jafri et al. 2013; Neumann et al. 2004; Gimenez-Roqueplo et al. 2003; Astuti et al. 2001a,b; Baysal et al. 2000), which encode the B and D subunits of the succinate dehydrogenase (SDH) complex (type II mitochondrial…”
BackgroundSelf-citationEgan, G., Khan, D. H., Lee, J. B., Mirali, S., Zhang, L., & Schimmer, A. D. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1227 · Cited by 54
“Likewise, germline mutations in succinate dehydrogenase lead to increased cellular levels of succinate (38) and are associated with the development of paragangliomas and pheochromocytomas (41, 42).”
BackgroundGhayee, H. K., Havekes, B., Corssmit, E. P. M., Eisenhofer, G., Hammes, S. R., Ahmad, Z., Tessnow, A. H., Lazúrová, I., Adams, K. T., Fojo, A. T., et al. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0214 · Cited by 53
“By contrast, mutations in the genes encoding succinate dehydrogenase (SDH) subunits B, C, and D cause extra-adrenal PGLs associated with familial PGL syndromes PGL4, PGL3, and PGL1 respectively (Baysal et al. 2000, Niemann & Muller 2000, Astuti et al. 2001).”
BackgroundInvestigation of the role of SDHB inactivation in sporadic phaeochromocytoma and neuroblastoma
Astuti, D., Morris, M. R., Krona, C. C., Abel, F., Gentle, D., Martinsson, T., Kogner, P., Neumann, H. P. H., Voutilainen, R., Eng, C., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602202 · Cited by 52
“Familial phaeochromocytoma or head and neck paraganglioma (HNPGL) kindreds with germline SDHD mutations demonstrate parent-of-origin effects on penetrance (Baysal et al, 2000; Astuti et al, 2001a).”
BackgroundMethodSelf-citationBandara, A. B., Drake, J. C., & Brown, D. A. (2021) · BMC Molecular and Cell Biology · doi:10.1186/s12860-021-00370-w · Cited by 56
Strosberg, J. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.11.009 · Cited by 49
Zantour, B., Guilhaume, B., Tissier, F., Louvel, A., Jeunemaître, X., Gimenez‐Roqueplo, A., & BERTAGNA, X. Y. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1510433 · Cited by 49
Genetic mechanisms of human hypertension and their implications for blood pressure physiology
Seidel, E., & Scholl, U. I. (2017) · Physiological Genomics · doi:10.1152/physiolgenomics.00032.2017 · Cited by 60
Metabolic Rewiring and the Characterization of Oncometabolites
Beyoğlu, D., & Idle, J. R. (2021) · Cancers · doi:10.3390/cancers13122900 · Cited by 58
“However, a metabolomic screen of hPheo1 pheochromocytoma cells and SDHB knockdown hPheo1 cells together with cancer tissues with and without SDHx mutations revealed that the polyamines spermidine and spermine were significantly elevated in relation to mutated succinate dehydrogenase.”
BackgroundGenetic and epigenetic profile of sporadic pheochromocytomas
Cascón, A., Ruiz-Llorente, S., Fraga, M. F., Leton, R., Telleria, D., Sastre, J., Diez, J. J., Diaz-Guerra, G. M., Perez, J. A. D., Benitez, J., et al. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2003.012658 · Cited by 53
Perturbations in hypoxia detection: A shared link between hereditary and sporadic tumor formation?
Sharifi, N., & Farrar, W. L. (2005) · Medical Hypotheses · doi:10.1016/j.mehy.2005.11.003 · Cited by 52
“Succinate dehydrogenase subunit (SDHB) mutations have been demonstrated in familial pheochromocytoma and familial paraganglioma [8].”
BackgroundMitochondrial diseases and the role of the yeast models
Rinaldi, T., Dallabona, C., Ferrero, I., Frontali, L., & Bolotin‐Fukuhara, M. (2010) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2010.00685.x · Cited by 56
“Mutations in SDHB, SDHC and SDHD are linked with dominantly inherited paragangliomas and phaechromocytomas (Devlin, 2000; Niemann & Muller, 2000; Astuti et al., 2001; Baysal et al., 2000; Goffrini et al., 2009), while mutations in SDHAF1 lead to infantile leukoencephalopathy (Ghezzi et al.”
BackgroundThe Adrenal Medulla and Extra-adrenal Paraganglia: Then and Now
Tischler, A. S., Pacák, K., & Eisenhofer, G. (2013) · Endocrine Pathology · doi:10.1007/s12022-013-9286-3 · Cited by 52
McCrary, H. C., Babajanian, E. E., Calquin, M., Carpenter, P. S., Casazza, G. C., Naumer, A., Greenberg, S. E., Kohlmann, W. K., Cannon, R. B., Monroe, M. M., et al. (2019) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2019.1110 · Cited by 47
Respiratory chain complex I is a mitochondrial tumor suppressor of oncocytic tumors
Kofler, B. (2010) · Frontiers in Bioscience-Elite · doi:10.2741/e247 · Cited by 49
“mitochondrial complex II, are associated with the development of these tumors (2) (3).”
BackgroundMutations associated with succinate dehydrogenase d ‐related malignant paragangliomas
Timmers, H. J. L. M., Pacák, K., Bertherat, J. Y., Lenders, J. W. M., Duet, M., Eisenhofer, G., Stratakis, C. A., Niccoli, P., Huy, P. T. B., Burnichon, N., et al. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03086.x · Cited by 53
Extracellular Succinate: A Physiological Messenger and a Pathological Trigger
Wu, K. K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311165 · Cited by 52
“Of note, mutations of SDH subunits, notably SDHB and SDHD, are detected in hereditary paragangliomas and pheochromocytomas [91,92].”
BackgroundMalignant pheochromocytomas and paragangliomas: a diagnostic challenge
Gimm, O., DeMicco, C., Perren, A. A., Giammarile, F., Walz, M. K., & Brunaud, L. (2011) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-011-0880-x · Cited by 51
Animal Mitochondria: Evolution, Function, and Disease
Tao, M., You, C., Zhao, R., Liu, S., Zhang, Z., Zhang, C., & Liu, Y. (2013) · Current Molecular Medicine · doi:10.2174/15665240113136660081 · Cited by 50
Pheochromocytoma and paraganglioma: molecular testing and personalized medicine
Burnichon, N., Buffet, A., & Gimenez‐Roqueplo, A. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000249 · Cited by 49
Charville, G. W., & Longacre, T. A. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000166 · Cited by 49
Aldera, A. P., & Govender, D. (2017) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2017-204677 · Cited by 55
Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies
Pang, Y. K., Liu, Y., Pacák, K., & Yang, C. (2019) · Cancers · doi:10.3390/cancers11040436 · Cited by 52
“In 2001, mutations in SDHB were also discovered in patients with familial PCPG [22].”
BackgroundRescue of TCA Cycle Dysfunction for Cancer Therapy
Marquez, J. C., Flores, J., Kim, A. H., Nyamaa, B., Nguyen, A. T. T., Park, N., & Han, J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122161 · Cited by 50
“The SDH complex gene-associated cancers include paragangliomas, pheochromocytomas, gastrointestinal stromal tumors (GIST), SDH-deficient renal cell carcinoma [54,55], thyroid tumors, neuroblastomas, testicular seminoma, and ovarian cancer [56].”
BackgroundErlic, Z., & Neumann, H. P. H. (2009) · HORMONES · doi:10.14310/horm.2002.1219 · Cited by 50
Rescorla, F. J. (2006) · Seminars in Pediatric Surgery · doi:10.1053/j.sempedsurg.2005.11.008 · Cited by 49
Simi, L., Sestini, R., Ferruzzi, P., Gaglianò, M. S., Gensini, F., Mascalchi, M., Guerrini, L., Pratesi, C., Pinzani, P., Nesi, G., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2004.030353 · Cited by 51
Pheochromocytoma: an updated scoping review from clinical presentation to management and treatment
Torres, J. S. S., Nati-Castillo, H. A., Cometa, L. A. V., Martínez, W. A. R., Asprilla, J., Castaño-Giraldo, C. M., Leonardo Sánchez, S., Heredia-Espín, M., Arias-Intriago, M., & Izquierdo‐Condoy, J. S. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1433582 · Cited by 63
Serine Biosynthesis Is a Metabolic Vulnerability in IDH2-Driven Breast Cancer Progression
Barnabas, G. D., Lee, J. S., Shami, T., Harel, M., Beck, L., Selitrennik, M., Jerby‐Arnon, L., Erez, N., Ruppin, E., & Geiger, T. (2021) · Cancer Research · doi:10.1158/0008-5472.can-19-3020 · Cited by 47
The Genetic Basis of Pheochromocytoma and Paraganglioma: Implications for Management
Shuch, B. M., Ricketts, C. J., Metwalli, A. R., Pacák, K., & Linehan, W. M. (2014) · Urology · doi:10.1016/j.urology.2014.01.007 · Cited by 47
Mitochondrial complex II and genomic imprinting in inheritance of paraganglioma tumors
Baysal, B. E. (2013) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2012.12.005 · Cited by 46
Anticancer effects of metformin on neuroendocrine tumor cells in vitro
Vlotides, G., Tanyeri, A., Spampatti, M. P., Zitzmann, K., Chourdakis, M., Spöttl, G., Maurer, J., Nölting, S., Göke, B., & Auernhammer, C. J. (2014) · HORMONES · doi:10.14310/horm.2002.1517 · Cited by 51
SDHC mutations in hereditary paraganglioma/pheochromocytoma
Müller, U., Troidl, C., & Niemann, S. (2005) · Familial Cancer · doi:10.1007/s10689-004-0621-1 · Cited by 46
“The investigation of other mitochondrial complex-II-subunit genes has shown that genes coding for subunits SDHC (PGL3) and SDHB (PGL4) can also be mutated in hereditary PGL/pheochromocytoma [4, 5].”
BackgroundBezawork‐Geleta, A., Saiyed, T., Dougan, D. A., & Truscott, K. N. (2014) · The FASEB Journal · doi:10.1096/fj.13-242420 · Cited by 44
Impact of LC-MS/MS on the laboratory diagnosis of catecholamine-producing tumors
Eisenhofer, G., Peitzsch, M., & McWhinney, B. C. (2016) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2016.01.027 · Cited by 47
Casey, R. T., Warren, A. Y., Martín, J., Challis, B., Rattenberry, E., Whitworth, J., Andrews, K. A., Roberts, T., Clark, G. R., West, H. D., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00562 · Cited by 43
“Gly12Ser) Tested for SDHB/C/D and VHL 7 60 (60) Unilateral RCC No No detectable mutation in SDHB or VHL No Unilateral PC 8 10 (26) Abdominal PGL No SDHB mutation No Unilateral RCC c.”
Self-citationThe 3PAs: An Update on the Association of Pheochromocytomas, Paragangliomas, and Pituitary Tumors
Xekouki, P., Brennand, A., Whitelaw, B., Pacák, K., & Stratakis, C. A. (2018) · Hormone and Metabolic Research · doi:10.1055/a-0661-0341 · Cited by 50
Metadata
- Authors
- Astuti, D., Latif, F., Dallol, A., Dahia, P. L. M., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R.
- Affiliations
- University of Birmingham (GB)
- Dana-Farber Cancer Institute (US)
- Royal Victoria Infirmary (GB)
- Queen Elizabeth Hospital (GB)
- Uppsala University (SE)
- University of Cambridge (GB)
- Corresponding author
- Maher, Eamonn R.
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2001-07
- Volume
- 69
- Issue
- 1
- Pages
- 49-54
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC1226047
- OpenAlex
- W2025719835
- Cited by
- 1,087
- References
- 28
- Citations by year
- 2026: 16 · 2025: 18 · 2024: 18 · 2023: 31 · 2022: 29 · 2021: 40 · 2020: 29 · 2019: 51 · 2018: 42 · 2017: 47 · 2016: 54 · 2015: 46 · 2014: 70 · 2013: 61 · 2012: 75
- FWCI
- 37.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 4401 d)
- Locations
- The American Journal of Human Genetics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- British Heart Foundation
- National Cancer Institute (P-30-CA-16058, P30CA016058)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- succinate dehydrogenase, SDHB, SDHC, pheochromocytoma, paraganglioma, germline mutations, mitochondrial dysfunction, sporadic pheochromocytoma, tumor suppressor, RET proto-oncogene, VHL, neurofibromatosis type 1
- MeSH terms
- Proto-Oncogene Mas, Amino Acid Sequence, Base Sequence, DNA Mutational Analysis, Female, Haplotypes, Humans, Male, Molecular Sequence Data, Mutation, Paraganglioma, Pedigree, Pheochromocytoma, Succinate Dehydrogenase, Sequence Alignment, Germ-Line Mutation, Loss of Heterozygosity, Genetic Predisposition to Disease, Mutation, Missense, Protein Subunits
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.